Transforming the Treatment of Neuromuscular Diseases
Driven by our proprietary Enhanced Delivery Oligonucleotide (EDO) platform, we are creating a pipeline of disease-modifying therapeutics with the potential to safely and effectively target the root cause of serious genetic diseases, with an initial focus on neuromuscular diseases.
Creating the new generation of genetic therapies
Advancing revolutionary therapies to treat degenerative neuromuscular diseases
Careers at PepGen
We’re seeking passionate individuals who can help us to create therapies to improve the future of people living with neuromuscular diseases
Latest Updates
2023-09-27T16:16:52
PepGen Announces Upcoming Presentations at the 28th Annual Congress of the World Muscle Society
Read Press ReleaseSorry, we couldn't find any posts. Please try a different search.